• Home
  • Indena S.P.A
  • Podcast: HPAPI Manufacturing: Challenges, Solutions & Innovations
Podcast
16 Mar 2022

Podcast: HPAPI Manufacturing: Challenges, Solutions & Innovations

Listen now

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme.

Growth in the highly potent active pharmaceutical ingredients segment means there is strong demand for specialist outsourcing solutions for their manufacture. CDMOs don’t just need to have the right equipment and facilities; they also need to convince sponsors that they possess the in-depth knowledge of safety practices and containment technology.

In this CPHI Worldwide podcast with Carlo Aloni, Production and Process Technology Director at Indena, we looked at the various challenges of HPAPI production, the latest innovative technologies and what Indena is currently working towards in this highly promising growth sector.

Content provided by our supplier

Indena S.P.A

  • IT
  • 2015
    On CPHI since
  • 5
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Nutraceuticals
View company profile

Other Content from Indena S.P.A (3)

  • News Indena: The next generation CDMO

    28 Sep 2023
  • From the Rainforest to the Clinic. Turning a High-Potency Rare Natural Product Into an Anticancer API

    Video From the Rainforest to the Clinic. Turning a High-Potency Rare Natural Product Into an Anticancer API

    Natural products can be characterized by complex structure, limited availability, and exceptional potency, whose combination makes it challenging their development as API. Success requires integration of expertise in different areas, including the construction of a sustainable supply chain for the starting biomass, the capacity to manipulate high-potency products in a GMP environment, and the versatility to strategically complement isolation with semi-synthesis, total synthesis and biotechnology. In this context, mutual thrust between the service provider company and the drug candidate owner is critical, and the successful development of the anticancer drug tigilanol tiglate will give the opportunity to address these issues.
    2024-10-24
  • CDMO services

    Whitepaper CDMO services

    We have a unique expertise in developing and manufacturing HPAPIs. The company is equipped with kilolabs (for clinical and small commercial batches) and large industrial suite for HPAPIs with an OEL>20 ng/m3.